Weight-loss drugs and hypertension

A Cochrane systematic review published on 19 June 2026 asked a question that sounds straightforward: do weight-loss drugs help people with hypertension live longer or avoid heart attacks and strokes^[1]? After screening trials of orlistat, phentermine-topiramate, naltrexone-bupropion, semaglutide (a GLP-1 receptor agonist), and tirzepatide (a dual GIP/GLP-1 agonist), the authors concluded that the evidence remains insufficient to answer it.

What the review covered

Led by Ulrike Spary-Kainz at the Medical University of Graz, the fourth update of this Cochrane review included eight randomised controlled trials with approximately 13,000 hypertensive participants followed for six to 48 months^[1]. The primary outcomes were all-cause mortality, cardiovascular morbidity, and adverse events. Secondary outcomes included changes in systolic and diastolic blood pressure and body weight.

This update added two new trials evaluating newer drugs: one trial of semaglutide (274 participants) and one of tirzepatide (788 hypertensive participants). The remaining six trials covered orlistat (four trials, 3,132 participants), phentermine-topiramate (one trial, 1,305 participants), and naltrexone-bupropion (one trial, 8,283 participants)^[1].

Key findings by drug

For orlistat, the oldest drug in the set and an intestinal lipase inhibitor rather than an incretin mimetic, the review found moderate-certainty evidence that it probably increases serious adverse events compared with placebo. Effects on mortality and cardiovascular outcomes were rated very low certainty, meaning the reviewers could draw no reliable conclusion^[1]. Orlistat's gastrointestinal side-effect profile is well documented, and the four included trials spanning over 3,000 participants still could not settle the cardiovascular question.

Phentermine-topiramate probably increased all adverse events versus placebo (moderate certainty), but its effects on mortality and cardiovascular morbidity were again very uncertain^[1]. Naltrexone-bupropion, tested in a single large trial of 8,283 participants, showed little difference in serious adverse events but probably increased overall adverse events (moderate certainty). None of these older agents provided the hard-endpoint reassurance clinicians would need to recommend them specifically for cardiovascular risk reduction in hypertensive patients.

The newer GLP-1 receptor agonists fared no better in this review, but for a different reason. Neither the semaglutide nor the tirzepatide trial reported results for the review's critical outcomes: all-cause mortality, cardiovascular morbidity, or serious adverse events in the hypertensive subgroup^[1]. The data simply was not provided. This is a reporting gap, not necessarily a safety signal. The SURMOUNT-1 trial for tirzepatide, for instance, demonstrated improvements in cardiometabolic measures alongside a mean body-weight reduction of up to 20.9% at 72 weeks on the highest dose^[4], but the published results did not break out cardiovascular endpoints for the hypertensive subset.

Why the gap matters

Hypertension affects an estimated 1.4 billion adults aged 30 to 79 worldwide, roughly one in three people in that age range^[2]. Weight loss is already recommended as a first-line intervention alongside medication, because excess weight raises blood pressure through multiple pathways. The clinical question is whether adding a weight-loss drug on top of standard antihypertensive therapy produces a net benefit on hard endpoints such as heart attack, stroke, and death, not just a number on a scale.

A 2026 review in Current Hypertension Reports noted that incretin-based therapies like semaglutide and tirzepatide significantly reduce body weight, blood pressure, and cardiovascular outcomes in large-scale trials^[3]. Those reviewers went further, arguing that the evidence supports use of these drugs in selected high-risk populations and suggesting an emerging role in future guideline recommendations. But those trials enrolled mixed populations, not exclusively hypertensive cohorts. The Cochrane authors' point is specific: unless future trials report separate results for people who have hypertension, the evidence base for this subgroup remains thin.

The industry-funding question

Seven of the eight trials in the review were industry-funded^[1]. The review authors flagged this as a limitation. Industry-sponsored weight-loss trials are typically designed to demonstrate efficacy on weight and metabolic markers, not to power the study for mortality or cardiovascular events in a hypertensive subgroup. That design choice is understandable from a regulatory-approval standpoint but leaves a gap in the clinical evidence base that independent funders have not yet filled.

What we do not yet know

The Cochrane review makes the gap explicit: "Overall, the evidence for people with hypertension remains insufficient to draw conclusions regarding the benefits of pharmacological weight loss in terms of reducing the risk of mortality or cardiovascular morbidity"^[1]. That does not mean these drugs are harmful for hypertensive patients. It means the right studies have not been done, or have not reported the right subgroup data.

Large cardiovascular outcome trials for GLP-1 agonists do exist. SELECT, for semaglutide, showed a 20% reduction in major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease. SURPASS-CVOT and SURMOUNT-related data for tirzepatide are accumulating^[4]. But the Cochrane framework requires that hypertension-specific subgroups be reported separately, and that bar has not been met. Until trial sponsors publish those breakdowns, or until independent investigators design hypertension-primary trials, systematic reviewers will keep reaching the same conclusion: we do not have enough data.

Patients taking weight-loss medications who also have hypertension should continue working with their healthcare provider to manage both conditions. This review does not change current prescribing practice. It highlights the need for better data so that future practice can be evidence-based for this specific population. Anyone considering starting or stopping a weight-loss medication should discuss the decision with a qualified clinician who can weigh individual cardiovascular risk factors.